Oct 27. 2017

Genestack Joins the Milner Therapeutics Institute

As sequencing technology shrinks to the size of a key ring and emerging technologies make it possible to track changes to the genome at single cell level, then all of a sudden genomics data becomes a streaming and wearable dataset,” says Imad Yassin, Vice President of bio data management company Genestack. He is explaining why an ecosystem approach is needed for drug discovery and how the company will support members of the Milner Therapeutics Institute in delivering this.

Read more


Sep 18. 2017

Hackathon stimulates innovation and creativity

New insights gained from genomic information are changing the way we diagnose disease, develop drugs and test for toxicity but there is a shortage of people with the skills and tools needed to analyse and interpret these data. To help build these skills the first Cambridge Bioinformatics Hackathon is to take place in the city on 25-27th September 2017.

Read more


Sep 08. 2017

Genestack offers 'missing link' for genomics drug discovery

“Genestack is providing an essential missing link between data and its analysis,” says Imad I. Yassin, recently appointed Vice President of Sales and Marketing for Genestack, the Cambridge-based biodata management company.

Read more


Sep 07. 2017

Visualising gene-trait networks for faster discovery

It is now possible for non-bioinformaticians to create knowledge-networks – a powerful way for biologists to visualise deep connections between genes and phenotypes – quickly and efficiently thanks to the integration of Rothamsted Research’s open-source KnetMiner software into the Genestack platform.

Read more


Jul 28. 2017

Is shortage of bioinformaticians holding back adoption of precision medicine?

Many key scientists lack essential skills in bioinformatics and this is potentially a bottleneck for therapeutic research in big pharma. Dr Misha Kapushesky, CEO of Genestack, will discuss how increasing pressure on bioinformaticians is slowing the pace of discovery in a webinar ‘Next-generation Sequencing: New Business Models in Diagnostics and Drug Development’ organised by Frost & Sullivan on 9th August.

Read more